Alvotech (ALVO) Stock Price, News & Analysis

Company Overview

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Key Stats

• Today's Range: $7.96 to $8.11
• 50-Day Range: $8.02 to $9.81
• 52-Week Range: $7.35 to $13.70
• Volume: 229,923 shs
• Average Volume: 490,472 shs
• Market Capitalization: $2.43 billion
• P/E Ratio: 35.09
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Moderate Buy

Alvotech Stock Analysis - MarketRank™

Alvotech scored higher than 55% of companies evaluated by MarketBeat, and ranked 711th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alvotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Alvotech has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alvotech are expected to grow in the coming year, from ($0.07) to $0.20 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alvotech is 35.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 268.93.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alvotech is 35.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.11.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.02% of the float of Alvotech has been sold short.

Short Interest Ratio / Days to Cover

Alvotech has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Alvotech has recently decreased by 34.32%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alvotech does not currently pay a dividend.

Dividend Growth

Alvotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.02% of the float of Alvotech has been sold short.

Short Interest Ratio / Days to Cover

Alvotech has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Alvotech has recently decreased by 34.32%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 1.02

News Sentiment

Alvotech has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Alvotech this week, compared to 6 articles on an average week.

Search Interest

Only 12 people have searched for ALVO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Alvotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alvotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.46% of the stock of Alvotech is held by insiders.

ALVO Stock Analysis - Frequently Asked Questions

How have ALVO shares performed this year?

Alvotech's stock was trading at $13.23 at the beginning of the year. Since then, ALVO shares have decreased by 39.0% and is now trading at $8.07.

How were Alvotech's earnings last quarter?

Alvotech (NASDAQ:ALVO) announced its quarterly earnings data on Wednesday, August, 13th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.40. The company earned $116.02 million during the quarter, compared to analyst estimates of $120.51 million. Alvotech had a net margin of 11.26% and a negative trailing twelve-month return on equity of 38.36%.
Read the conference call transcript.

Who are Alvotech's major shareholders?

Alvotech's top institutional shareholders include Oaktree Capital Management LP (0.52%), Legal & General Group Plc (0.22%), Geode Capital Management LLC (0.08%) and Gilder Gagnon Howe & Co. LLC (0.06%).

How do I buy shares of Alvotech?

Shares of ALVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alvotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alvotech investors own include Micron Technology (MU), Arista Networks (ANET), United Microelectronics (UMC), Weatherford International (WFRD), NVIDIA (NVDA), PACCAR (PCAR) and Axcelis Technologies (ACLS).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 8/29/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALVO
• Previous Symbol: NYSE:ALVO
• CIK: 1898416
• Web: www.alvotech.com
• Phone: 354-422-4500
• Fax: N/A
• Employees: 1,032
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Alvotech: $14.00
• High Price Target: $14.00
• Low Price Target: $14.00
• Potential Upside/Downside: +73.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.23
• Trailing P/E Ratio: 18.30
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$231.86 million
• Net Margins: 11.26%
• Pretax Margin: -44.43%
• Return on Equity: -38.36%
• Return on Assets: 9.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.82
• Quick Ratio: 1.27

Sales & Book Value

• Annual Sales: $491.98 million
• Price / Sales: 4.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.57) per share
• Price / Book: -14.16

Miscellaneous

• Outstanding Shares: 301,480,000
• Free Float: 300,095,000
• Market Cap: $2.43 billion
• Optionable: Not Optionable
• Beta: 0.11